FINNENCE ▪ THE WIRE FILE
THE WIRE · № 90960
Company■ Mixed
New Phase 3 trial: A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Older Adults — Pfizer
KINDCompany
DIRECTION■ Mixed
SOURCES1
ENTITIES0
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
THE MACHINE IS STILL READING THIS ITEM — ANALYSIS LANDS WITHIN MINUTES OF INGESTION.
FULL DISPATCH
Sponsor: Pfizer; Status: Not Yet Recruiting; Conditions: Respiratory Syncytial Virus (RSV); Interventions: RSVpreF (Regimen A), RSVpreF (Regimen B); Enrollment: 750 (estimated); First posted: 2026-10-21; NCT: NCT07885956
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
NO ENTITY LINKS AT DISPLAY CONFIDENCE YET.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.